Assessing Pulse Biosciences (PLSE) Valuation After The nPulse Cardiac Catheter Ablation Pivot

Simply Wall St.03-23

Pulse Biosciences (PLSE) has placed its nPulse Cardiac Catheter Ablation System at the center of its plans, following European feasibility data in Atrial Fibrillation and upcoming pivotal studies and ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2621674571?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","is_english":true,"pubTime":"2026-03-23 01:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621674571","market":"nz","top_or_hot":-1,"title":"Assessing Pulse Biosciences (PLSE) Valuation After The nPulse Cardiac Catheter Ablation Pivot","media":"Simply Wall St.","content":"<div>\n<p>Pulse Biosciences (PLSE) has placed its nPulse Cardiac Catheter Ablation System at the center of its plans, following European feasibility data in Atrial Fibrillation and upcoming pivotal studies and ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-plse/pulse-biosciences/news/assessing-pulse-biosciences-plse-valuation-after-the-npulse\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Pulse Biosciences (PLSE) Valuation After The nPulse Cardiac Catheter Ablation Pivot</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Pulse Biosciences (PLSE) Valuation After The nPulse Cardiac Catheter Ablation Pivot\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-23 01:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nasdaq-plse/pulse-biosciences/news/assessing-pulse-biosciences-plse-valuation-after-the-npulse><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pulse Biosciences (PLSE) has placed its nPulse Cardiac Catheter Ablation System at the center of its plans, following European feasibility data in Atrial Fibrillation and upcoming pivotal studies and ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-plse/pulse-biosciences/news/assessing-pulse-biosciences-plse-valuation-after-the-npulse\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-plse/pulse-biosciences/news/assessing-pulse-biosciences-plse-valuation-after-the-npulse","article_id":"2621674571","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-plse/pulse-biosciences/news/assessing-pulse-biosciences-plse-valuation-after-the-npulse","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2621674571","pubTimestamp":1774199235,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Pulse Biosciences (PLSE) has placed its nPulse Cardiac Catheter Ablation System at the center of its plans, following European feasibility data in Atrial Fibrillation and upcoming pivotal studies and conference presentations.\nSee our latest analysis for Pulse Biosciences.\nThese AFib data and the new focus on the nPulse Cardiac Catheter program come after a strong run, with a 90 day share price return of 45.39% and a very large 3 year total shareholder return. At the same time, the 1 year...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","PLSE":"Pulse Biosciences, Inc."},"translate_title":"评估nPulse心导管消融术后Pulse Biosciences(PLSE)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PLSE":1.5},"content_text":"Pulse Biosciences (PLSE) has placed its nPulse Cardiac Catheter Ablation System at the center of its plans, following European feasibility data in Atrial Fibrillation and upcoming pivotal studies and conference presentations. See our latest analysis for Pulse Biosciences. These AFib data and the new focus on the nPulse Cardiac Catheter program come after a strong run, with a 90 day share price return of 45.39% and a very large 3 year total shareholder return. At the same time, the 1 year total shareholder return of 37.61% and 5 year total shareholder return of 4.29% together suggest that momentum has recently been building from a relatively flat longer term base. If this kind of medical technology story interests you, it can be useful to see what else is gaining attention in the sector and beyond through the 36 healthcare AI stocks. With shares up sharply over the past year and the price still sitting below a US$30 analyst target, the key question now is whether Pulse Biosciences is still undervalued or if the market is already pricing in future growth. AdvertisementMost Popular Narrative: 50% Overvalued Pulse Biosciences last closed at $22.10, compared with a most followed narrative fair value estimate of $22.00, which points to a modest premium and a lot of expectation already in the price.  Advancing clinical programs for the nPulse cardiac surgical clamp and nPulse 360 Catheter in atrial fibrillation, including FDA IDE approval, breakthrough designation, and expanding EU feasibility data, creates a path to entry in a high value EP and cardiac surgery market that can expand the company’s addressable revenue base and long term earnings power.  Read the complete narrative. Curious what kind of revenue ramp and margin shift that vision assumes? This narrative leans on sharp top line growth and a rich future earnings multiple. The numbers behind that view are anything but conservative. Result: Fair Value of $22 (OVERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this situation could change quickly if clinical trials do not clearly outperform existing treatments, or if higher expenses and limited revenue keep cash burn elevated. Find out about the key risks to this Pulse Biosciences narrative. Next Steps If this mix of optimism and concern around Pulse Biosciences leaves you undecided, it may be helpful to act promptly and evaluate the data yourself using the 1 key reward and 3 important warning signs. Looking for more investment ideas? Do not stop with a single stock when there are clear, data driven ways to spot other opportunities using the Simply Wall St Screener that many investors overlook.  Target potential mispricings by reviewing companies that screen as 53 high quality undervalued stocks before attention fully shifts their way. Secure more predictable income streams by checking out the 13 dividend fortresses that could suit a yield focused watchlist. Prioritise resilience by focusing on 68 resilient stocks with low risk scores that may help balance out bolder positions in your portfolio.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621674571","isCrawlerRequest":true}